The FDA has rejected the submission of Gilead for approval of filgotinib in rheumatoid arthritis. With the FDA requesting to see data from an ongoing clinical trial, Gilead is unlikely to be able to refill until after the middle of next year, pushing it even further behind its rivals for …
Read More »FDA rejects Gilead’s filterbuster for blockbuster over concerns about toxicity
